Opthea Comes with Announcements regarding its new Leaders

Opthea Limited (NASDAQ: OPT; ASX: OPT), a clinical-stage biopharmaceutical company, has announced a significant change in its executive team. Dr. Megan Baldwin, the current Chief Executive Officer, will transition to the role of founder and Chief Innovation Officer, effective immediately. This strategic shift reflects the company’s focus on advancing its presence in the U.S. and its global commercialization strategy for sozinibercept (OPT-302). In addition to this transition, Opthea has appointed two U.S.-based executives, Dr. Frederic Guerard, as the new Chief Executive Officer and Peter Lang as the Chief Financial Officer.

Dr. Guerard and Lang both bring extensive experience in the healthcare industry, with a proven track record of building and expanding organizations, overseeing research and development initiatives, leading commercial operations, and managing financial aspects. They have successfully provided strategic direction and guided companies through crucial phases of corporate, clinical, and commercial growth.

Dr. Jeremy Levin, Chairman of Opthea’s board of directors, welcomed the new appointments, stating, “On behalf of the board, I am pleased to welcome Fred Guerard and Peter Lang to Opthea’s leadership team. Both come to Opthea with impressive credentials to position Opthea for future growth and success. We are also excited to create a new and essential role for Megan to continue to enhance the opportunity for sozinibercept and Opthea’s pipeline of next-generation therapeutics for retinal diseases. Megan has dedicated much of her career to making Opthea what it is today and continues to be a critical member of the leadership team and board of directors.”

Dr. Megan Baldwin expressed her thoughts on the transition, saying, “Recognizing that Opthea is entering a critical stage of its corporate growth trajectory, with an expanded team in the U.S. and increased focus on advancing the commercialization strategy for sozinibercept, I am pleased to welcome both Frederic and Peter to their new roles and working with them to lead Opthea’s transition to its next phase of growth.”

Dr. Guerard also shared his excitement about joining Opthea, saying, “I’m excited to join Opthea at such an important time for the company. I believe it’s now well-positioned to disrupt the eye disease treatment landscape, highlighted by sozinibercept’s potential to become the first drug, when used in combination, to deliver superior visual gains compared to standard of care in wet AMD. I wish to extend my gratitude to the board for this opportunity and look forward to working with Megan, Peter, and the entire team as we work to advance Opthea to ultimately become a premier ophthalmology company.”

Peter Lang expressed his gratitude, stating, “I am honored to have this opportunity to work with Fred, Megan, the management team, and the board to efficiently grow the business and bring significant value to patients, clinicians, and investors. The Opthea team continues to build a unique biotech and realize the full potential of its pipeline with a differentiated, first-in-class product candidate in the late stage of pivotal Phase 3 clinical trials addressing a real need for wet AMD patients.”

Have you read?
Richest countries in the world by GDP per capita in 2023.
Countries With The Highest And Lowest Average Salaries, 2023.
Best Fashion Schools In The World.
Best Business Schools In The World.
The World’s Best CEOs And C-Suite Executives, 2023.

This report/news/ranking/statistics has been prepared only for general guidance on matters of interest and does not constitute professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is given as to the accuracy or completeness of the information contained in this publication, and, to the extent permitted by law, CEOWORLD magazine does not accept or assume any liability, responsibility or duty of care for any consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.

Email Address*

Name